問卷

TPIDB > Search Result

Search Result

篩選

List

70Cases

2022-02-01 - 2028-02-15

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-08-01 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2017-02-10 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Recruiting13Sites

2022-03-01 - 2028-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2015-09-15 - 2019-09-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated11Sites

2024-03-28 - 2026-08-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-11-29 - 2027-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2015-02-25 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Terminated10Sites

2017-10-01 - 2020-09-30

Phase II/III

A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    Unituxin®

Participate Sites
5Sites

Terminated5Sites

劉劍英
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-02-28 - 2022-12-31

Phase II

A Phase 2, open-label study of orally administered PAX-1 therapy in patients with brain metastases secondary to non-small cell lung cancer
  • Condition/Disease

    Brain metastases secondary to non-small cell lung cancer

  • Test Drug

    PAX-1

Participate Sites
8Sites

Recruiting8Sites